Table 1.
Details of male and female participants by randomized treatment group
| DG | CON | |
|---|---|---|
| n = 72 | n = 65 | |
| Age | 53 ± 8 | 53 ± 8 |
| Sex | ||
| Male, n (%) | 31 (43) | 26 (40) |
| Pre-menopausal female, n (%) | 15 (21) | 15 (23) |
| Post-menopausal female, n (%) | 26 (36) | 24 (37) |
| Ethnicity | ||
| White European, n (%) | 66 (92) | 61 (94) |
| Asian, n (%) | 6 (8) | 4 (6) |
| BMI (kg/m2) | 25.0 ± 3.3 | 26.5 ± 3.7 |
| Fasting plasma total cholesterol (mmol/L) | 5.3 ± 1.0 | 5.3 ± 0.9 |
| Fasting plasma HDL cholesterol (mmol/L) | 1.6 ± 0.4 | 1.5 ± 0.5 |
| Fasting plasma TG (mmol/L) | 1.0 ± 0.6 | 1.2 ± 0.5 |
| Fasting plasma glucose (mmol/L) | 5.3 ± 0.5 | 5.2 ± 0.4 |
| Seated systolic BP (mmHg) | 118 ± 14 | 119 ± 13 |
| Seated diastolic BP (mmHg) | 76 ± 8 | 78 ± 9 |
| 10-year risk of CVD men (%) | 7.6 ± 5.3 | 7.9 ± 5.7 |
| 10-year risk of CVD women (%) | 3.7 ± 3.1 | 4.9 ± 3.4 |
Mean ± SD. 10-year risk of CVD estimated using QRISK-2. No significant differences between groups: two-sample t test or Mann–Whitney U test
DG dietary guidelines, CON control, BMI body mass index, BP blood pressure, CVD cardiovascular disease, HDL high-density lipoprotein